All About Stem Cell Therapy and Research
Hey everyone! This is our final project, a documentary about stem cell therapy and research, the difference lines of stem cells and the dilemmas. Thank you f...
By: NVW Stem Cells
See more here:
All About Stem Cell Therapy and Research - Video
BBC iScience Stem Cell Therapy
A fun, engaging and relevant programme, inspiring the viewer to consider the science within and how scientific process can be used to test ideas and develop theories, rather than just looking...
By: Lammas Science
The rest is here:
BBC iScience Stem Cell Therapy - Video
VANCEBURG | A Lewis County man is working his way toward stem cell therapy in an attempt to help him walk again.
Jennifer Richardson, a long-time friend of Anthony Schumacher, said Schumacher was involved in an accident in December 2012, which left him paralyzed.
According to Richardson, Schumacher was in a comma for a few days and has no memory of the accident.
"He was going to work when his tire blew out and he wrecked the car," Richardson said. "He was in a coma for days and when he woke up he was paralyzed from the belly button down and couldn't remember anything."
Tammy Moore, Schumacher's mother, said he keeps a positive attitude about his situation.
"He's a happy person," she said. "He works out everyday and tries to learn new things about his situation and the procedure."
Moore said she would like to see Schumacher get the therapy.
"I don't know a lot about it. I'm still learning about it," she said. "But, from what I've seen, it's a good thing that can help him get at least some of the feeling back, if not all. I want to see him get it, if it can help."
Schumacher said he looks forward to the possibility of the procedure, too.
"I'm hopeful," he said. "I want to get it done. I've been trying to do my research and I would like to do this."
Go here to read the rest:
Lewis County man hopes for stem cell therapy
Hoofcare Today - Episode 19 - MRI Findings Stem Cell Treatment
Hoofcare Today - Episode 19 - Featured on "The Horse Show" with Rick Lamb. Gene Ovnicek talks with Dr. Ross Rich about the use of MRI to help diagnosis lamen...
By: HoofCareToday
See the original post here:
Hoofcare Today - Episode 19 - MRI Findings
Treatment for copd using stem cells: Video Ripped Off
http://www.regenestem.com/ We want you to know that the technology exists that has proven to not only manage your COPD but to possibly reverse the effects of...
By: Jason Ratzlaff
Go here to see the original:
Treatment for copd using stem cells: Video Ripped Off - Video
A Newport Beach nonprofit donated $150,000 toward stem cell research that could slow or reverse heart damage in patients, including those with a specific muscular dystrophy condition, the organization announced last week.
Coalition Duchenne gave the money to a Cedars-Sinai Heart Institute team developing a treatment that could help treat Duchenne muscular dystrophy patients who develop heart disease, according to a news release from the coalition.
Boys with Duchenne are born with damage to their hearts that worsens over time, according to Dr. Ron Victor, associate director of the Cedars-Sinai Heart Institute.
"If we can use stem cells to slow or stop heart damage, it could help stall progression of the disease," he said in a prepared statement.
The institute's experimental treatment involves removing a raisin-size piece of heart muscle that is used to grow the stem cells.
Researchers have seen an average 50% reduction in muscle damage following a heart attack when those cells are injected back into the patient, according to the release.
"Each year, 20,000 boys are born with Duchenne," said Catherine Jayasuriya, who founded Coalition Duchenne in 2010 after her son was diagnosed with cardiomyopathy associated with the disease. "Many do not live into their 20s and we lose many to cardiac issues. We need to focus on changing the course of the disease. We hope that working with cardiac stem cells is one way we will eventually change that outcome."
Jeremiah Dobruck
Twitter: @jeremiahdobruck
Visit link:
$150,000 donation to fund stem cell research
HIALEAH (CBSMiami) A team of Hialeah veterinarians performed a groundbreaking medical procedure on a dog to help him walk again.
Brando, a 9-year-old German shepherd, received an innovative two-part stem cell therapy at Paradise Animal Clinic in Hialeah on Wednesday. Its the first time this type of therapy has been performed in Florida.
The dog had been paralyzed from the waist down since January and used a doggie wheelchair to get around.
Vets said that he had a skin infection that paralyzed his lungs and then spread to a disc in his back. The infection caused 80 percent of Brandos leg muscles to weaken.
We were totally emotionally destroyed. Kids were crying, wife was upset, I was upset, said owner Manuel Bouza. Obviously the issue was he was so sick whether we put him down because hes paralyzed or whether we deal with it.
Bouza said that they wanted to do whatever they could to help him. One day, he stumbled across a video on YouTube about a dog in Great Britain who had received a stem cell treatment and he became interested.
With no proven options for recovery, they decided to try an experimental stem cell procedure never performed before in Florida.
This is a last ditch effort, said Bouza.
During the procedure, surgeons took fat from Brandos stomach and processed out the stem cells which were then re-injected into his spinal cord. They hope the cells will regenerate tissue and help Brando become more mobile.
The idea is that stem cells are able to go to a given place in the body and repair, said said animal surgeon Jose Gorostiza. Hopefully they will help the cells that are there function again, the new ones.
Here is the original post:
Paralyzed Dog Receives Stem Cell Therapy
Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 3 hours ago The picture shows a 9.5-day-old mouse embryo including extra-embryonic tissue. The red region marks embryonic stem cells in the extra-embryonic yolk sac. Embryonic stem cells are not normally able to do this, but when cells are pushed backwards in development as described in Morgani et al. Credit: Sophie Morgani, University of Copenhagen.
Scientists at the Danish Stem Cell Center, DanStem, at the University of Copenhagen have discovered that they can make embryonic stem cells regress to a stage of development where they are able to make placenta cells as well as the other fetal cells. This significant discovery, published in the journal Cell Reports today, has the potential to shed new light on placenta related disorders that can lead to problematic pregnancies and miscarriages.
Embryonic stem cells can make all kinds of adult cells in the human body such as muscle, blood or brain cells. However, these embryonic stem cells are created at a point when the embryo has already lost the ability to make extra-embryonic tissue such as placenta and yolk sac. Extra-embryonic tissues are formed at the very earliest stage of development right after fertilization and are essential for the growth of the embryo and its implantation in the womb.
A team of scientists at the Danish Stem Cell Center, DanStem, at the University of Copenhagen have shown that it is possible to rewind the developmental state of embryonic stem cells. By maintaining mouse embryonic stem cells under certain conditions, they found that cells appear to regress and resemble extremely early embryo cells that can form any kind of cell including placenta and yolk sac cells.
"It was a very exciting moment when we tested the theory," says Professor Josh Brickman from DanStem. "We found that not only can we make adult cells but also placenta, in fact we got precursors of placenta, yolk sac as well as embryo from just one cell."
Sophie Morgani, PhD student at DanStem and first author of the paper, which was published in the scientific journal Cell Reports today adds: "This new discovery is crucial for the basic understanding of the nature of embryonic stem cells and could provide a way to model the development of the organism as a whole, rather than just the embryonic portion. In this way we may gain greater insight into conditions where extra-embryonic development is impaired, as in the case of miscarriages."
LIF protein plays a crucial role
Brickman and colleagues grew their embryonic stem cells in a solution containing LIF, which is a protein known to somehow support embryonic stem cells but also for its role in implantation of the embryo into the uterus. As implantation is stimulated by the cells that will become the placenta, not the embryo, these roles appeared to be contradictory. The DanStem study resolved this contradiction by revealing that LIF helps maintain the cells in their regressed, early stage of development.
"In our study we have been able to see the full picture unifying LIF's functions: What LIF really does, is to support the very early embryo state, where the cells can make both embryonic cells and placenta. This fits with LIFs' role in supporting implantation," Josh Brickman says.
Explore further: Sorting stem cells
Originally posted here:
Rewinding development: A step forward for stem cell research
Public release date: 6-Jun-2013 [ | E-mail | Share ]
Contact: Renatt Brodsky newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine
Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the online journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease. Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells.
"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."
In conjunction with the laboratory of Matthew J. Evans, PhD, from the Department of Microbiology at Icahn School of Medicine at Mount Sinai, investigators demonstrated the functionality of the liver cells generated from the progenitors, as the liver cells can be infected by the hepatitis C virus, a property restricted to liver cells exclusively.
A critical discovery in this research was finding that the novel progenitor has a receptor protein on its cell surface called KDR, or vascular endothelial growth factor receptor 2, which until now, was thought to be restricted to endothelial cells that form vessels, the progenitors for endothelial cells and the progenitors blood cells. The research team showed that activation of KDR on these novel liver progenitors differentiates them into mature liver cells. Additionally, work in a mouse model revealed similar cells, indicating that the progenitors are conserved from mouse to human, and therefore, they must be "important cells with promising potential for cell therapy in treating liver disease," explained Dr. Gouon-Evans.
Next, the research team will examine specifically whether these liver cells obtained from human embryonic stem cells in a dish help repair injured livers in preclinical animal models of liver disease.
###
Funding for this study was provided by The Black Family Stem Cell Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Robin Chemers Neustein Postdoctoral Fellowship, the American Cancer Society, and Pew Charitable Funds.
About the Black Family Stem Cell Institute
Read the original:
Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration
June 6, 2013 Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease. Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells.
"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."
In conjunction with the laboratory of Matthew J. Evans, PhD, from the Department of Microbiology at Icahn School of Medicine at Mount Sinai, investigators demonstrated the functionality of the liver cells generated from the progenitors, as the liver cells can be infected by the hepatitis C virus, a property restricted to liver cells exclusively.
A critical discovery in this research was finding that the novel progenitor has a receptor protein on its cell surface called KDR, or vascular endothelial growth factor receptor 2, which until now, was thought to be restricted to endothelial cells that form vessels, the progenitors for endothelial cells and the progenitors blood cells. The research team showed that activation of KDR on these novel liver progenitors differentiates them into mature liver cells. Additionally, work in a mouse model revealed similar cells, indicating that the progenitors are conserved from mouse to human, and therefore, they must be "important cells with promising potential for cell therapy in treating liver disease," explained Dr. Gouon-Evans.
Next, the research team will examine specifically whether these liver cells obtained from human embryonic stem cells in a dish help repair injured livers in preclinical animal models of liver disease.
Funding for this study was provided by The Black Family Stem Cell Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Robin Chemers Neustein Postdoctoral Fellowship, the American Cancer Society, and Pew Charitable Funds.
About The Black Family Stem Cell Institute The Black Family Stem Cell Institute is Mount Sinai's foundation for both basic and disease-oriented research on embryonic and adult stem cells. The therapeutic use of stem cells is a promising area of medicine for the decades ahead and researchers are examining why stem cells function in certain types of niches, microenvironments, and pockets of activity. Investigators are working to break the code in stem cell communication by determining how stem cells signal one another and other cells. The new knowledge that will result from this research holds the promise of diagnostic and therapeutic breakthroughs.
Studies show that it is possible to reprogram adult skin cells into cells that are very similar to embryonic stem cells. Once stem cells can be grown and differentiated in a controlled way to replace degenerated cells and repair tissues, medical science may then be able to diagnose and cure many intractable diseases at their earliest stages, such as type 1 diabetes, Parkinson's disease, various cardiovascular diseases, liver disease, and cancer.
See the original post here:
New liver cell for cellular therapy to aid in liver regeneration